Liquid chromatographic determination of sotalol in plasma and urine employing solid-phase extraction and fluorescence detection.
A liquid chromatographic method using a solid-phase extraction procedure for the quantification of sotalol in plasma and urine is described. Sotalol is eluted from an extraction column with ethyl acetate-acetonitrile (1:2) and, after separation by reversed-phase high-performance liquid chromatography on a mu Bondapak C18 column, is quantified by fluorescence detection at excitation and emission wavelengths of 240 and 310 nm, respectively. The method has been demonstrated to be linear over the concentration ranges 10-6000 ng/ml in plasma and 0.5-100 micrograms/ml in urine. Mean inter-assay accuracy of the method for plasma ranged from 93 to 100% and for urine from 102 to 114%; precision ranged from 0.5 to 1.6% for plasma over a concentration range of 200-4000 ng/ml and for urine from 0.7 to 2.0% at concentrations of 2-50 micrograms/ml. Mass spectrometry confirmed the presence of sotalol in isolated chromatographic fractions of plasma and urine extracts from subjects given sotalol orally.
Department of Metabolism and Pharmacokinetics, Bristol-Myers Company, Evansville, IN 47721.
M J
MJ
Bartek
M
M
Vekshteyn
M P
MP
Boarman
D G
DG
Gallo
D002851:Chromatography, High Pressure Liquid; D002853:Chromatography, Liquid; D004355:Drug Stability; D008401:Gas Chromatography-Mass Spectrometry; D006801:Humans; D013015:Sotalol / Q000032:analysis* / Q000097:blood / Q000652:urine; D013050:Spectrometry, Fluorescence
D013015:Sotalol